Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 4, Issue 10, Pages 1866-1889
Publisher
MDPI AG
Online
2015-10-24
DOI
10.3390/jcm4101866
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Kidney Disease End Points in a Pooled Analysis of Individual Patient–Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes
- (2015) Mark E. Cooper et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
- (2015) James D. Lewis et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes
- (2015) Emanuela Lapice et al. Journal of Translational Medicine
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
- (2015) L. Zanoli et al. TheScientificWorldJOURNAL
- Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
- (2015) L. Zanoli et al. Scientific World Journal
- The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years
- (2015) Alberto Martínez-Castelao et al. Journal of Clinical Medicine
- Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes
- (2014) Luca De Nicola et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat
- (2014) Peter Vavrinec et al. Current Vascular Pharmacology
- Insulin Sensitivity and Albuminuria: The RISC Study
- (2014) Stefan Pilz et al. DIABETES CARE
- The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
- (2014) Angelo Avogaro et al. DIABETES CARE
- Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
- (2014) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Linagliptin Blocks Renal Damage in Type 1 Diabetic Rats by Suppressing Advanced Glycation End Products-Receptor Axis
- (2014) S. Nakashima et al. HORMONE AND METABOLIC RESEARCH
- The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Protects against Dyslipidemia-Related Kidney Injury in Apolipoprotein E Knockout Mice
- (2014) Jingjing Li et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The potential for renoprotection with incretin-based drugs
- (2014) Tetsuhiro Tanaka et al. KIDNEY INTERNATIONAL
- Sitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
- (2014) Catarina Marques et al. MEDIATORS OF INFLAMMATION
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
- (2014) Yoshihito Fujita et al. Journal of Diabetes Investigation
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Dapagliflozin in patients with type 2 diabetes mellitus
- (2014) Theodosios D. Filippatos et al. Therapeutic Advances in Endocrinology and Metabolism
- Renal effects of dapagliflozin in patients with type 2 diabetes
- (2014) Merlin C. Thomas Therapeutic Advances in Endocrinology and Metabolism
- Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
- (2013) John P.H. Wilding ANNALS OF INTERNAL MEDICINE
- Glucagon-like Peptide-1 Receptor Agonist Liraglutide Inhibits Endothelin-1 in Endothelial Cell by Repressing Nuclear Factor-Kappa B Activation
- (2013) Yao Dai et al. CARDIOVASCULAR DRUGS AND THERAPY
- Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
- (2013) P.-H. Groop et al. DIABETES CARE
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes
- (2013) Koji Sakata et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies
- (2013) M. Ferwana et al. DIABETIC MEDICINE
- Gliquidone decreases urinary protein by promoting tubular reabsorption in diabetic Goto-Kakizaki rats
- (2013) Jian-Ting Ke et al. JOURNAL OF ENDOCRINOLOGY
- Sodium–glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
- (2013) Richard E. Gilbert KIDNEY INTERNATIONAL
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
- (2013) Minsuk Kim et al. NATURE MEDICINE
- The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
- (2013) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease
- (2012) Usha Panchapakesan et al. CLINICAL SCIENCE
- Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKC Activation in Diabetes
- (2012) A. Mima et al. DIABETES
- The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients
- (2012) J.-M. Halimi DIABETES & METABOLISM
- Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease
- (2012) Ai-li Sun et al. Diabetes & Vascular Disease Research
- Renal Podocyte Injury in a Rat Model of Type 2 Diabetes Is Prevented by Metformin
- (2012) Junghyun Kim et al. Experimental Diabetes Research
- DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy
- (2012) Markus L. Alter et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Exenatide Reduces Urinary Transforming Growth Factor-ß1 and Type IV Collagen Excretion in Patients with Type 2 Diabetes and Microalbuminuria
- (2012) Hong Zhang et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Renal and Cardiac Effects of DPP-4 Inhibitors from Preclinical Development to Clinical Research
- (2012) Berthold Hocher et al. KIDNEY & BLOOD PRESSURE RESEARCH
- Peroxisome proliferator-activated receptor- activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in Type 2 diabetes
- (2012) E. Y. Lee et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
- (2011) Scott C. Thomson et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy
- (2011) J. M. Lachin et al. Clinical Journal of the American Society of Nephrology
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)
- (2011) Cristina Mega et al. Experimental Diabetes Research
- Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches
- (2011) Emaad M. Abdel-Rahman et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- PPAR 2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies
- (2011) S. De Cosmo et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control
- (2010) P. Anagnostis et al. DIABETES OBESITY & METABOLISM
- Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]
- (2010) Sachiko Hattori ENDOCRINE JOURNAL
- Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway
- (2010) Ana I. Morales et al. KIDNEY INTERNATIONAL
- Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial
- (2010) Faramarz Ismail-Beigi et al. LANCET
- Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes
- (2010) Jitendra Vaghasiya et al. REGULATORY PEPTIDES
- Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes: New results from the ADVANCE trial
- (2009) S. Zoungas et al. DIABETES CARE
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
- Phlorizin Prevents Glomerular Hyperfiltration but not Hypertrophy in Diabetic Rats
- (2008) Slava Malatiali et al. Experimental Diabetes Research
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
- (2008) Peter Gæde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started